PROOVSTATION
3.3.2020 17:21:11 CET | Business Wire | Press release
ProovStation and GCA, a major European actor in the transport and industrial logistics sector, signed today a partnership with the aim of creating commercial synergies and supporting the development of the solutions offered by ProovStation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005747/en/
The aim of this agreement is to install 30 stations in all the automotive logistic sites of the Groupe Charles André. The deployment will start in April with the installation of the first 2 stations at Corbas (Lyon) and Fleury Merogis (Paris) sites.
For Serge Agneray, Director General of GCA Automotive Logistics division, this new equipment is part of their desire to find innovative solutions with added value for their customers.
GCA's Automotive Logistic branch, in strong growth, is composed of 32 sites in Europe. GCA offers many services to manufacturers, rental companies and vehicle sellers (new and used): transport (with 3.2 million vehicles per year), storage, preparation, maintenance, remarketing, 3D photo, and soon the automated inspection through the solution of ProovStation.
Thanks to their advanced Artificial Intelligence system, ProovStation gantries will allow GCA to offer a fully automated vehicle inspection in 3 seconds. During the passage of the car under the gantry, scratches of the order of a millimeter can be detected, which increases the precision and reduces the cost linked to the inspection.
“We are glad to count GCA as one of our trusted partners and we are looking forward to start this great collaboration which constitutes an important stage in our development. Furthermore, supporting in its activity a key player in the sector such as GCA, is a great recognition for our solution. It brings us closer to our goal, which is: make ProovStation the international standard for the car inspection” says Cédric BERNARD, CEO of ProovStation.
Delphine André, CEO of GCA adds "We are delighted to establish this partnership with ProovStation, a Start Up that shifts the lines in a profession in profound change, and will allow us to benefit our customers from innovative solutions that are always more efficient"
Last January, the Start Up announced its first commercial agreement with BCA Group, the European leader in used vehicle remarketing, aiming to deploy 40 inspection gantries, across Europe, in 13 countries. With this new contract, ProovStation further confirms the strong legitimacy and value of its vehicle inspection solution for the automotive industry.
ABOUT PROOVSTATION
ProovStation is a Deeptech Start Up specialized in Computer Vision. Its ambition is to industrialize, automate and standardize the global automotive inspection process. It reduces the total cost of car inspection and increase the efficiency of the whole process to improve the client and collaborator experience. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. This approach allows to cover all the angles and to capture all damages with an accuracy of one millimeter. The gantry identifies, quantifies and localizes all damages present on the vehicle through its Artificial Intelligence. It delivers a time stamped, geo-located and secured report via the Block Chain. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
ABOUT GCA
Founded in 1932, and currently leaded by Delphine André, granddaughter of its founder, Groupe Charles André (GCA) has developed and diversified its historical activities as road transporter of dangerous good. GCA is now able to intervene on the entire Supply chain in fields like aeronautics, food, automotive, Construction and minerals, chemistry, defense, energy, environment, rail and urban logistics. In 2019, GCA achieved a turnover of 1.4 Billion euros. In 15 countries, GCA employs over 9,400 people. GCA cultivates the values of autonomy, respect for commitments, humility and teamwork. The company attaches great importance to safety, quality of its human resources and training.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005747/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom